California Life Sciences Association (CLSA) today urged Governor Jerry Brown to sign Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and awaits action by Governor Brown, who has until Sept. 30 to sign or veto the legislation.
CLSA was a proud sponsor and participant of the 6th Annual Rally for Medical Research & National Day of Action on Sept. 13-14, 2018, an annual event that brings together more than 300 organizations to call on our nation’s policymakers to make funding for National Institutes of Health (NIH) a national priority.
On Sept. 11, CLSA co-hosted a multi-state life sciences association Congressional briefing on the patent system and how it works toward encouraging innovation in the development of life saving technologies.
Assembly Bill 375, the California Consumer Privacy Act, will require companies that store large amounts of data, such as Google, Facebook, Twitter, and others, to disclose what kinds of data they collect, and give consumers more control over how that data is shared.
The California Life Sciences Association (CLSA) joined a coalition, which includes fellow life sciences trade associations, providers, insurers, and a number of other key stakeholders, to address the concerns related to HIPAA preemption and clinical trials data in the recently enacted AB 375, “The California Consumer Privacy Act of 2018” (“Privacy Act”), which will become effective January 1, 2020.
August has been a successful month for CLSA in educating the California state legislature on issues of critical importance to the life sciences industry in California.
CLSA’s federal government relations team provides an update on the outlook for key federal life sciences legislation likely to be addressed this year in Congress.
This August, CLSA participated in a medical technology industry roundtable discussion with Congressman Khanna (D-Fremont). Organized by AdvaMed and hosted by BD Biosciences in San Jose, attendees included representatives from CLSA members BD and Roche, and other medtech innovators including Boston Scientific, Elekta, Stryker and Varian.
In early August, CLSA organized a 2-day tour of multiple life sciences sector companies and research institutions across the Bay Area for Congressman Tony Cárdenas (D-San Fernando Valley), and his Washington DC-based staff. Cárdenas and our CLSA Federal Government Relations team visited & toured regional CLSA member companies including: Sutro Biopharma (San Carlos), 23andMe (Mountain View), Johnson & Johnson Innovation | JLABS (South San Francisco), and BioMarin (San Rafael and Novato).
California’s new Consumer Privacy Act (AB 375), the toughest data privacy law in the nation, will impose stringent new requirements on the state’s high-profile tech companies in 2020. Its impacts on the life sciences industry, though, remain unclear. CLSA’s State Government Relations team sat down with BioWorld to discuss what the measure means for innovative biomedical companies.